[Fundamental and clinical studies on XXXX in the field of obstetrics and gynecology].

@entity1712 @entity16397 @entity7288 @entity298 @entity281 @entity5647 @entity12945 @entity4134 @entity5646
Fundamental and clinical studies on @entity5646 ( @entity5647 ), a new synthetic @entity16397 antibiotic, were performed and following results were obtained. Concentration of @entity5647 was examined in serum, internal genital tissues and retroperitoneal fluid after a single intravenous administration of 1 g dose. The venous serum level of @entity5647 was 114.0 micrograms/ml at 10 minutes after the administration, then decreased to 7.0 micrograms/ml at 3 hours. Since concentration of @entity5647 in examined tissues showed wide variation, it was irrelevant to calculate transfer ratio. Concentration in retroperitoneal fluid made the peak of 40.0 +/- 22.6 micrograms/ml at 1 hour after the administration, then slowly decreased to 13.4 +/- 3.2 micrograms/ml at 6 hours. Judging from above data, the transfer of @entity5647 to retroperitoneal fluid was favorable. In clinical trial, @entity5647 was given to 17 cases with obstetrical and @entity281 such as @entity7288 , uterine @entity4134 , @entity298 , @entity12945 and lymphocystitis. The efficacy was evaluated as excellent in 2 cases, good in 12 and poor in 3, and efficacy rate was 82.4%. No side effects were observed in any of the cases. In laboratory findings, transient elevation of liver function in 2 cases and @entity1712 in 1 case were noticed.
